BioSpace News Archive

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended March 31, 2022.

Bruker Corporation and TOFWERK AG today announced a strategic partnership for high-speed, ultra-sensitive applied and industrial analytical solutions, in conjunction with a Bruker minority investment in TOFWERK.

Castle Biosciences, Inc. today announced that for the second year, it is a national sponsor of The Sun Bus, a mobile clinic that provides free skin checks and sun safety education across numerous U.S. states.

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2022.

UNYQ Inc. , a leader in the field of 3D-printed prosthetic wears, is introducing the new UNYQ FOOT, an innovative approach to making prosthetic feet for persons with amputations.

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended March 31, 2022.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the first quarter ended March 31, 2022, and provided recent corporate updates.

Pathnostics, a leading precision diagnostic testing and development company, today announced that it will present results of a Medicare database analysis designed to determine rates of adverse outcomes, medical resource utilization, and costs with Guidance UTI compared to standard urine culture (SUC) in patients with complicated urinary tract infections (cUTI).

Accuray Incorporated (NASDAQ: ARAY) announced today that clinical studies continue to validate the versatility of the company’s CyberKnife® and TomoTherapy® platforms, including the next-generation Radixact® System.

Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today introduced a milestone technology release, setting the bar as the most comprehensive, end-to-end platform to fully orchestrate study conduct for decentralized clinical trials (DCTs) and increasingly agile designs that require both remote and on-premise management.